Navigation Links
ITN type 1 diabetes study identifies subset of patients with strong response to therapy
Date:8/15/2013

WA, Seattle (August 15, 2013) Primary results from a new clinical trial show that patients with type 1 diabetes treated with the monoclonal antibody teplizumab (MacroGenics, Inc.) exhibit greater preservation of C-peptide, a biomarker of islet cell function, compared to controls. Further analyses identified a discrete subset of the treatment group that demonstrated especially robust responses ("responders"), suggesting that these patients could be identified prior to treatment. The trial, entitled "Autoimmunity-Blocking Antibody for Tolerance in Recently Diagnosed Type 1 Diabetes" (AbATE), was conducted by the Immune Tolerance Network (ITN). The results are available online and will be published in the November issue of the journal Diabetes.

The AbATE study, led by Kevan Herold, MD (Yale University), tested teplizumab, which targets the CD3 receptor found on T cells, in patients with new-onset type 1 diabetes. CD3 is required for T-cell activation, which can lead to the destruction of insulin-producing beta cells. A previous ITN study with teplizumab showed that a single course of the drug slowed C-peptide decline in new-onset patients for a year, after which the effects waned. The aim of the AbATE study was to test whether C-peptide preservation could be prolonged by administering two courses of teplizumab, one year apart.

In this open-label, Phase II study, 77 new-onset patients (ages 8 to 30 years old) were randomized to receive either teplizumab or a control. Those in the treatment arm received the scheduled treatment consisting of two 14-day courses of teplizumab, one year apart. Both arms received intensive diabetes care from certified diabetes educators and were followed for two years. The primary endpoint compared C-peptide preservation between the two groups.

After two years, the teplizumab-treated group showed significantly greater preservation of C-peptide (75-percent higher responses compared to the control group).

Further analysis revealed that within the treatment arm two groups of patients could be distinguished based on their C-peptide levels: one group, considered "responders" (22/49), showed very little C-peptide decline over the course of the study (only a 6 percent reduction from baseline), while the "non-responders" (27/49) exhibited a similar rate of C-peptide decline as the control group (less than 40-percent reduction from baseline).

Investigators measured various biomarkers and cell types that might distinguish between these two groups. They found that, at trial entry, "responders" had lower hemoglobin A1c levels (a marker of glucose concentration in the blood) and used less insulin at baseline, compared to "non-responders". Differences in specific T-cell subsets also distinguished between the two groups at baseline, suggesting that immune status might contribute to drug responsiveness. However, further studies will be required to confirm these results.

"This overall approach to identifying characteristics of individuals most likely to respond to therapies shows great promise because the responders in this study experienced a robust and prolonged drug effect," said Dr. Herold. "This type of response has not been seen in other studies of immune therapies."

Type 1 diabetes is a disease marked by immune destruction of insulin-producing beta cells in the pancreas. New-onset patients usually have 20 to 40 percent of their normal beta cell mass remaining, which is still capable of producing insulin. Preserving this remaining mass, even temporarily, could improve long-term clinical outcomes.

Immune modulators, like teplizumab, represent a promising means of inducing tolerance; however, no drug has been shown to prevent or reverse disease, and only a few have temporarily delayed disease progression. The ability to identify a subgroup of patients who may be more responsive to therapy could greatly enhance the clinical use of immune modulators and improve outcomes for those patients. Further analyses with specimens collected from the AbATE study are ongoing to understand the mechanism of response.


'/>"/>

Contact: Philip Bernstein, Ph.D.
ITNCommunications@immunetolerance.org
240-235-6132
Immune Tolerance Network
Source:Eurekalert

Related biology news :

1. Diabetes Research Institute develops oxygen-generating biomaterial
2. New study shines light on barriers to diabetes care in NYC Bangladeshi community
3. Commonly used diabetes drug may help to prevent primary liver cancer
4. Approach to diabetes self-management too narrow, study suggests
5. Gut microbiota transplantation may prevent development of diabetes and fatty liver disease
6. From feast to famine: A metabolic switch that may help diabetes treatment
7. Increased fructose consumption may deplete cellular energy in patients with obesity and diabetes
8. Jack Spratt diabetes gene identified
9. Diabetes drug makes brain cells grow
10. Obesity plus low vitamin D may add up to a greater risk of diabetes
11. Joslin researchers gain new understanding of diabetes and kidney disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... 16, 2017  Genos, a community for personal ... has received Laboratory Accreditation from the College of ... to laboratories that meet stringent requirements around quality, ... processes. "Genos is committed to maintaining ... We,re honored to be receiving CAP accreditation," said ...
(Date:2/13/2017)... , Feb. 13, 2017  RSA Conference -- ... platform that is designed to enhance fraud detection ... release in the RSA Fraud & Risk Intelligence ... organizations to leverage additional insights from internal and ... to better protect their customers from targeted cybercrime ...
(Date:2/10/2017)... DUBLIN , Feb 10, 2017 ... PharmaBiotech,s new report "Personalized Medicine - Scientific and Commercial ... ... in personalized medicine. Diagnosis is integrated with therapy for selection ... emphasis on early detection and prevention of disease in modern ...
Breaking Biology News(10 mins):
(Date:2/21/2017)... ... February 21, 2017 , ... During ... connected digital health applications, announced a partnership with Redox, a leader in cloud-based ... to many clinical systems while keeping data secure in the cloud. , The ...
(Date:2/21/2017)... ... February 21, 2017 , ... ... Treximo will pair its $200M operational capacity with its strategic internal leadership ... in areas affecting quality and operational management. With office locations in ...
(Date:2/21/2017)... , Feb. 21, 2017   Logicalis Healthcare Solutions ... IT solutions and managed services provider ( www.us.logicalis.com ), ... Desk for Epic. The new service will help hospital ... resources by giving physicians, nurses and other clinicians immediate ... tier-one support. This will allow hospital IT staff to ...
(Date:2/20/2017)... - BioAmber Inc. (NYSE: BIOA ) announced today that Jean-Francois ... the company,s COO, has been named President, effective immediately.  ... Fabrice has overseen the construction, start-up and operation of the manufacturing ... the Mitsui JV.  Fabrice has also been extensively involved in the ... ...
Breaking Biology Technology: